Bicycle Therapeutics (BCYC) EBT (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly EBT came in at -$50.2 million in Q2 2026, up 36.55% YoY from -$36.8 million in Q2 2025, and up 17.16% on a QoQ basis from -$60.7 million in Q1 2026.
Bicycle Therapeutics (BCYC) EBT (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of EBT data on file, last reported at -$50.2 million in Q2 2026.
- Quarterly EBT rose 36.55% year-over-year to -$50.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$195.3 million (up 23.11% YoY) and the FY2025 annual result came in at -$225.5 million, down 25.53% from the prior year.
- EBT grew to -$50.2 million in Q2 2026, from -$60.7 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$25.5 million in Q4 2025 to a low of -$79.2 million in Q2 2025.
- A 5-year average of -$45.3 million and a median of -$45.4 million in 2023 frame the typical range for EBT.
- The widest YoY moves for EBT: up 56.53% in 2025, down 129.78% in 2025.
- Tracing BCYC's EBT over 5 years: stood at -$32.4 million in 2022, then slumped by 62.04% to -$52.6 million in 2023, then slipped by 11.79% to -$58.8 million in 2024, then soared by 56.53% to -$25.5 million in 2025, then tumbled by 96.75% to -$50.2 million in 2026.
- The last three EBT figures came in at -$50.2 million (Q2 2026), -$60.7 million (Q1 2026), and -$25.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | -50.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.24 Mn |
| Mar 31, 2026 | -60.65 Mn |
| Dec 31, 2025 | 206.57 Mn |
| Sep 30, 2025 | -58.90 Mn |
| Jun 30, 2025 | -79.18 Mn |
| Mar 31, 2025 | -61.84 Mn |
| Dec 31, 2024 | -52.94 Mn |
| Sep 30, 2024 | -54.25 Mn |
| Jun 30, 2024 | -39.70 Mn |
| Mar 31, 2024 | -26.91 Mn |
| Dec 31, 2023 | 134.20 Mn |
| Sep 30, 2023 | -47.63 Mn |
| Jun 30, 2023 | -43.12 Mn |
| Mar 31, 2023 | -39.68 Mn |
| Dec 31, 2022 | -32.43 Mn |
| Sep 30, 2022 | -28.59 Mn |
| Jun 30, 2022 | -27.28 Mn |
| Mar 31, 2022 | -27.98 Mn |
| Dec 31, 2021 | -18.79 Mn |
| Sep 30, 2021 | -15.09 Mn |